News & Updates

Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.

A recent study involving Dutch teenagers has found that a higher number of episodes of >20 minutes of continuous smartphone use may lead to more myopic refractive errors. Such association does not exist in those with high outdoor exposure.

The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.

Several older adults in Singapore have low appendicular skeletal muscle mass index (ASMI), particularly those who are at high risk for malnutrition, according to a recent study. Smoking, drinking, and low bone mass are other warning signs of low ASMI.

In the second-line treatment of patients advanced oesophageal cancer, the use of programmed cell death 1 (PD-1) inhibitors yields more favourable outcomes than chemotherapy across multiple patient subgroups, according to the results of a meta-analysis.

New drug applications approved by US FDA as of 16-30 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.